Australian Clinical Labs Ltd (AU:ACL) has released an update.
Australian Clinical Labs Limited has appointed E+P as the broker for its on-market share buy-back program, targeting its ordinary fully paid shares. The market has been updated with this information as of September 13, 2024, following the initial notification on August 29, 2024. This strategic financial decision may influence the company’s stock performance and investor interest.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
